Company news: Novartis and Boehringer Ingelheim

Share this article:
Novartis is setting itself up to dominate the generic dermatology market. The company said Thursday that generics subsidiary Sandoz is purchasing Fougera Pharmaceuticals for $1.5 billion in cash. The company estimated the merged businesses will have about $620 million in generic dermatology sales, the majority of which will be in the US.

Boehringer Ingelheim launched what it called the largest observational study of non-valvular atrial fibrillation (NVAF) patients. The goal is to enroll 56,000 patients from 50 countries and fill all 56,000 slots by the next decade. NVAF is a form of atrial fibrillation, which is known as an irregular heartbeat but which is also linked to stroke-causing blood clots. A registry, known as GLORIA-AF, will track the long-term impact of anti-clotting treatments, including warfarin, acetylsalicylic acid, BI's anticoagulant Pradaxa (dabigatran etexilate mesylate) and J&J/Bayer's blood thinner Xarelto (rivaroxaban).
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.